U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Melanoma

MedGen UID:
1663701
•Concept ID:
C4727838
•
Neoplastic Process

Definition

Melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Professional guidelines

PubMed

Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment.
Bender MJ, McPherson AC, Phelps CM, Pandey SP, Laughlin CR, Shapira JH, Medina Sanchez L, Rana M, Richie TG, Mims TS, Gocher-Demske AM, Cervantes-Barragan L, Mullett SJ, Gelhaus SL, Bruno TC, Cannon N, McCulloch JA, Vignali DAA, Hinterleitner R, Joglekar AV, Pierre JF, Lee STM, Davar D, Zarour HM, Meisel M
Cell 2023 Apr 27;186(9):1846-1862.e26. Epub 2023 Apr 6 doi: 10.1016/j.cell.2023.03.011. PMID: 37028428Free PMC Article
Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
Biermann J, Melms JC, Amin AD, Wang Y, Caprio LA, Karz A, Tagore S, Barrera I, Ibarra-Arellano MA, Andreatta M, Fullerton BT, Gretarsson KH, Sahu V, Mangipudy VS, Nguyen TTT, Nair A, Rogava M, Ho P, Koch PD, Banu M, Humala N, Mahajan A, Walsh ZH, Shah SB, Vaccaro DH, Caldwell B, Mu M, Wünnemann F, Chazotte M, Berhe S, Luoma AM, Driver J, Ingham M, Khan SA, Rapisuwon S, Slingluff CL Jr, Eigentler T, Röcken M, Carvajal R, Atkins MB, Davies MA, Agustinus A, Bakhoum SF, Azizi E, Siegelin M, Lu C, Carmona SJ, Hibshoosh H, Ribas A, Canoll P, Bruce JN, Bi WL, Agrawal P, Schapiro D, Hernando E, Macosko EZ, Chen F, Schwartz GK, Izar B
Cell 2022 Jul 7;185(14):2591-2608.e30. doi: 10.1016/j.cell.2022.06.007. PMID: 35803246Free PMC Article
Treatment of Advanced Melanoma in 2020 and Beyond.
Jenkins RW, Fisher DE
J Invest Dermatol 2021 Jan;141(1):23-31. Epub 2020 Apr 5 doi: 10.1016/j.jid.2020.03.943. PMID: 32268150Free PMC Article

Recent clinical studies

Etiology

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A
J Immunother Cancer 2022 Dec;10(12) doi: 10.1136/jitc-2022-005755. PMID: 36600653Free PMC Article
Immune checkpoint inhibitors in melanoma.
Carlino MS, Larkin J, Long GV
Lancet 2021 Sep 11;398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X. PMID: 34509219
Treatment of Advanced Melanoma in 2020 and Beyond.
Jenkins RW, Fisher DE
J Invest Dermatol 2021 Jan;141(1):23-31. Epub 2020 Apr 5 doi: 10.1016/j.jid.2020.03.943. PMID: 32268150Free PMC Article
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD
N Engl J Med 2019 Oct 17;381(16):1535-1546. Epub 2019 Sep 28 doi: 10.1056/NEJMoa1910836. PMID: 31562797
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators
N Engl J Med 2015 Jun 25;372(26):2521-32. Epub 2015 Apr 19 doi: 10.1056/NEJMoa1503093. PMID: 25891173

Diagnosis

Cutaneous melanoma.
Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA
Lancet 2023 Aug 5;402(10400):485-502. Epub 2023 Jul 24 doi: 10.1016/S0140-6736(23)00821-8. PMID: 37499671
The Treatment of Advanced Melanoma: Therapeutic Update.
Villani A, Potestio L, Fabbrocini G, Troncone G, Malapelle U, Scalvenzi M
Int J Mol Sci 2022 Jun 7;23(12) doi: 10.3390/ijms23126388. PMID: 35742834Free PMC Article
Immune checkpoint inhibitors in melanoma.
Carlino MS, Larkin J, Long GV
Lancet 2021 Sep 11;398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X. PMID: 34509219
Overcoming Immune Evasion in Melanoma.
Eddy K, Chen S
Int J Mol Sci 2020 Nov 26;21(23) doi: 10.3390/ijms21238984. PMID: 33256089Free PMC Article
Cutaneous Melanoma-A Review in Detection, Staging, and Management.
Hartman RI, Lin JY
Hematol Oncol Clin North Am 2019 Feb;33(1):25-38. doi: 10.1016/j.hoc.2018.09.005. PMID: 30497675

Therapy

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A
J Immunother Cancer 2022 Dec;10(12) doi: 10.1136/jitc-2022-005755. PMID: 36600653Free PMC Article
Immune checkpoint inhibitors in melanoma.
Carlino MS, Larkin J, Long GV
Lancet 2021 Sep 11;398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X. PMID: 34509219
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD
N Engl J Med 2019 Oct 17;381(16):1535-1546. Epub 2019 Sep 28 doi: 10.1056/NEJMoa1910836. PMID: 31562797
Melanoma.
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S
Lancet 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. PMID: 30238891
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators
N Engl J Med 2015 Jun 25;372(26):2521-32. Epub 2015 Apr 19 doi: 10.1056/NEJMoa1503093. PMID: 25891173

Prognosis

Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA
Nature 2022 Nov;611(7934):155-160. Epub 2022 Oct 26 doi: 10.1038/s41586-022-05368-8. PMID: 36289334Free PMC Article
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD
N Engl J Med 2019 Oct 17;381(16):1535-1546. Epub 2019 Sep 28 doi: 10.1056/NEJMoa1910836. PMID: 31562797
Melanoma.
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S
Lancet 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. PMID: 30238891
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J
N Engl J Med 2017 Oct 5;377(14):1345-1356. Epub 2017 Sep 11 doi: 10.1056/NEJMoa1709684. PMID: 28889792Free PMC Article
Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA
N Engl J Med 2015 Jan 22;372(4):320-30. Epub 2014 Nov 16 doi: 10.1056/NEJMoa1412082. PMID: 25399552

Clinical prediction guides

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ
J Clin Oncol 2023 May 20;41(15):2724-2735. Epub 2023 Feb 13 doi: 10.1200/JCO.22.02072. PMID: 36780608Free PMC Article
Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.
Betof Warner A, Corrie PG, Hamid O
Clin Cancer Res 2023 May 15;29(10):1835-1854. doi: 10.1158/1078-0432.CCR-22-1922. PMID: 36485001Free PMC Article
Treatment of Advanced Melanoma in 2020 and Beyond.
Jenkins RW, Fisher DE
J Invest Dermatol 2021 Jan;141(1):23-31. Epub 2020 Apr 5 doi: 10.1016/j.jid.2020.03.943. PMID: 32268150Free PMC Article
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD
N Engl J Med 2019 Oct 17;381(16):1535-1546. Epub 2019 Sep 28 doi: 10.1056/NEJMoa1910836. PMID: 31562797
Pembrolizumab (Keytruda).
Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL
Hum Vaccin Immunother 2016 Nov;12(11):2777-2789. Epub 2016 Jul 11 doi: 10.1080/21645515.2016.1199310. PMID: 27398650Free PMC Article

Recent systematic reviews

Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A, Tanda ET, Croce E, Catalano F, Ceppi M, Bruzzone M, Cecchi F, Arecco L, Fraguglia M, Pronzato P, Genova C, Del Mastro L, Lambertini M, Spagnolo F
Eur J Cancer 2023 Jul;188:64-79. Epub 2023 Apr 24 doi: 10.1016/j.ejca.2023.04.010. PMID: 37196485
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G
Ann Oncol 2019 Dec 1;30(12):1902-1913. doi: 10.1093/annonc/mdz398. PMID: 31566658
Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review.
Rubio-Rodríguez D, De Diego Blanco S, Pérez M, Rubio-Terrés C
Pharmacoeconomics 2017 Sep;35(9):879-893. doi: 10.1007/s40273-017-0517-1. PMID: 28551858
Systematic review of psychosocial outcomes for patients with advanced melanoma.
Dunn J, Watson M, Aitken JF, Hyde MK
Psychooncology 2017 Nov;26(11):1722-1731. Epub 2016 Nov 7 doi: 10.1002/pon.4290. PMID: 27696578
Melanoma chemoprevention.
Francis SO, Mahlberg MJ, Johnson KR, Ming ME, Dellavalle RP
J Am Acad Dermatol 2006 Nov;55(5):849-61. Epub 2006 Sep 18 doi: 10.1016/j.jaad.2006.04.014. PMID: 17052492

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...